BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Karageorgopoulos DE, Allen J, Bhagani S. Hepatitis C in human immunodeficiency virus co-infected individuals: Is this still a “special population”? World J Hepatol 2015; 7(15): 1936-1952 [PMID: 26244068 DOI: 10.4254/wjh.v7.i15.1936]
URL: https://www.wjgnet.com/1948-5182/full/v7/i15/1936.htm
Number Citing Articles
1
María-Carlota Londoño, Mar Riveiro-Barciela, Adriana Ahumada, Raquel Muñoz-Gómez, Mercé Roget, María J. Devesa-Medina, Miguel Ángel Serra, Carmen A. Navascués, Carme Baliellas, Teresa Aldamiz-Echevarría, María L. Gutiérrez, Benjamín Polo-Lorduy, Isabel Carmona, Salvador Benlloch, Lucía Bonet, Javier García-Samaniego, Miguel Jiménez-Pérez, Senador Morán-Sánchez, Ángeles Castro, Manuel Delgado, Francisco Gea-Rodríguez, Ignacio Martín-Granizo, María Luisa Montes, Luís Morano, Manuel A. Castaño, Ignacio de los Santos, Montserrat Laguno, Juan Emilio Losa, Marta Montero-Alonso, Antonio Rivero, Cristina de Álvaro, Amanda Manzanares, Josep Mallolas, Guillermina Barril, Emilio González-Parra, Luisa García-Buey, Yury E. Khudyakov. Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice – Vie-KinD studyPLOS ONE 2019; 14(9): e0221567 doi: 10.1371/journal.pone.0221567
2
Cristina Stasi, Caterina Silvestri, Roberto Berni, Maurizia Rossana Brunetto, Anna Linda Zignego, Cristina Orsini, Stefano Milani, Liana Ricciardi, Andrea De Luca, Pierluigi Blanc, Cesira Nencioni, Donatella Aquilini, Alessandro Bartoloni, Giampaolo Bresci, Santino Marchi, Franco Filipponi, Piero Colombatto, Paolo Forte, Andrea Galli, Sauro Luchi, Silvia Chigiotti, Alessandro Nerli, Giampaolo Corti, Rodolfo Sacco, Paola Carrai, Angelo Ricchiuti, Massimo Giusti, Paolo Almi, Andrea Cozzi, Silvia Carloppi, Giacomo Laffi, Fabio Voller, Francesco Cipriani. Epidemiological, demographic and clinical data on chronic viral hepatitis C in TuscanyCurrent Medical Research and Opinion 2019; 35(4): 661 doi: 10.1080/03007995.2018.1482264
3
Saman Mohazzab-Torabi, Fardin Dolatimehr, Heidar Sharafi, Mahdi Safi-Abadi , Mohammad Saeid Rezaee-Zavareh, Ehsan Bayatpour, Hamidreza Karimi-Sari, Seyed Moayed Alavian. Treatment of HCV Infection with Direct-Acting Antiviral Agents in Patients with HIV/HCV Co-Infection: A Systematic ReviewHepatitis Monthly 2018; (In Press) doi: 10.5812/hepatmon.82971
4
Hossam Abdelaziz, Heba Omar, Mahmoud Khalil, Ahmed Cordie, Rahma Mohamed, Mohamed AbdAllah, Mohammed Hamdy Abdel Maksoud, Naeema El Garhy, Lamiaa Ali, Magdy El Serafy, Gamal Esmat, Wahid Doss. Real-life experience of treating HCV co-infection among HIV-infected population in Egypt: single-center experienceExpert Review of Anti-infective Therapy 2022; 20(5): 789 doi: 10.1080/14787210.2022.2004117
5
Aline Vitali Grando, Paulo Roberto Abrão Ferreira, Mário Guimarães Pessôa, Daniel Ferraz de Campos Mazo, Carlos Eduardo Brandão-Mello, Tânia Reuter, Ana de Lourdes Candolo Martinelli, Mário Peribanez Gonzalez, Ana Catharina Seixas-Santos Nastri, Aléia Faustina Campos, Max Igor Banks Ferreira Lopes, José David Urbaez Brito, Maria Cássia Mendes-Corrêa. Peginterferon still has a place in the treatment of hepatitis C caused by genotype 3 virusRevista do Instituto de Medicina Tropical de São Paulo 2017; 59(0) doi: 10.1590/s1678-9946201759067
6
Fernanda Malta, Karine Vieira Gaspareto, Gaspar Lisboa-Neto, Flair José Carrilho, Maria Cássia Mendes-Correa, João Renato Rebello Pinho. Prevalence of naturally occurring NS5A resistance-associated substitutions in patients infected with hepatitis C virus subtype 1a, 1b, and 3a, co-infected or not with HIV in BrazilBMC Infectious Diseases 2017; 17(1) doi: 10.1186/s12879-017-2817-7
7
Mark Nelson, Rafael Rubio, Adriano Lazzarin, Svetlana Romanova, Annie Luetkemeyer, Brian Conway, Jean-Michel Molina, Dong Xu, Subasree Srinivasan, Simon Portsmouth. Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected PatientsJournal of Interferon & Cytokine Research 2017; 37(3): 103 doi: 10.1089/jir.2016.0082
8
Cristina Stasi, Caterina Silvestri, Fabio Voller. Update on Hepatitis C Epidemiology: Unaware and Untreated Infected Population Could Be the Key to EliminationSN Comprehensive Clinical Medicine 2020; 2(12): 2808 doi: 10.1007/s42399-020-00588-3
9
Kentaro Matsuura, Yasuhito Tanaka. Host genetic variations associated with disease progression in chronic hepatitis C virus infectionHepatology Research 2018; 48(2): 127 doi: 10.1111/hepr.13042
10
I. P. Balmasova, M. S. Aristanbekova, E. S. Malova, R. I. Sepiashvili. MECHANISMS OF INTERACTION OF VIRAL CAUSATIVE AGENTS IN PATIENTS CO-INFECTED WITH HUMAN IMMUNODEFICIENCY AND HEPATITIS C VIRUSESJournal of microbiology, epidemiology and immunobiology 2016; 93(5): 101 doi: 10.36233/0372-9311-2016-5-101-109
11
James Daniel Millard, Jaimie Henry, Syed Shoaib Rizvi, Mark Nelson. Direct-acting antivirals for acute hepatitis C in HIV-infected MSMAIDS 2016; 30(13): 2137 doi: 10.1097/QAD.0000000000001157
12
Edison Mayanja, Livingstone S. Luboobi, Juma Kasozi, Rebecca N. Nsubuga, Raul Alcaraz. Mathematical Modelling of HIV-HCV Coinfection Dynamics in Absence of TherapyComputational and Mathematical Methods in Medicine 2020; 2020: 1 doi: 10.1155/2020/2106570
13
Khashayar Hesamizadeh, Heidar Sharafi, Mohammad Saeid Rezaee-Zavareh, Bita Behnava, Seyed Moayed Alavian. Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting AntiviralsHepatitis Monthly 2016; 16(4) doi: 10.5812/hepatmon.37089
14
Damien Ulveling, Sigrid Le Clerc, Aurélie Cobat, Taoufik Labib, Josselin Noirel, Vincent Laville, Cédric Coulonges, Wassila Carpentier, Bertrand Nalpas, Markus H. Heim, Thierry Poynard, Andreas Cerny, Stanislas Pol, Pierre‐Yves Bochud, François Dabis, Ioannis Theodorou, Yves Lévy, Dominique Salmon, Laurent Abel, Stéphanie Dominguez, Jean‐François Zagury. A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virus‐coinfected patientsHepatology 2016; 64(5): 1462 doi: 10.1002/hep.28695
15
David Rey, Patrice Muret, Lionel Piroth. Optimum combination therapy regimens for HIV/HCV infectionExpert Review of Anti-infective Therapy 2016; 14(3): 299 doi: 10.1586/14787210.2016.1147952